Table 1 Baseline patient characteristics.
All Patients (n = 76) | No significant TR (n = 51) | Significant TR (n = 25) | p - Value | |
|---|---|---|---|---|
Gender (female), n (%) | 28 (37%) | 15 (29%) | 13 (52%) | 0.08 |
Age (years) | 74 (64–81) | 72 (69–74) | 75 (71–79) | 0.15 |
Peak aortic jet velocity (m/s) | 3.4 (3.1–3.6) | 3.3 (3.2–3.5) | 3.3 (3.2–3.5) | 0.76 |
Aortic mean gradient (mmHg) | 27 (22–33) | 28 (26–29) | 26 (24–29) | 0.29 |
Aortic valve area (cm2) | 0.79 (0.68–0.90) | 0.82 (0.78–0.87) | 0.73 (0.66–0.80) | 0.03 |
TAPSE (mm) | 20 (14–24) | 21 (18–23) | 17 (13–20) | 0.07 |
RV free-wall strain (%) | 19 (15–26) | 21 (17–26) | 18 (12–24) | 0.37 |
Left ventricular ejection fraction (%) | 33 (29–38) | 32 (29–36) | 31 (23–38) | 0.68 |
PA systolic pressure (mmHg) | 54 (39–62) | 48 (44–52) | 59 (54–64) | 0.0012 |
Interventricular septal thickness (cm) | 13 (12–14) | 13 (13–14) | 13 (12–14) | 0.27 |
Coronary artery disease, n (%) | 44 (58%) | 33 (64%) | 11 (44%) | 0.13 |
Hypertension, n (%) | 47 (62%) | 33 (64%) | 14 (56%) | 0.62 |
Diabetes mellitus, n (%) | 32 (42%) | 18 (35%) | 14 (56%) | 0.14 |
Hypercholesterolemia, n (%) | 44 (58%) | 32 (63%) | 12 (48%) | 0.32 |
COPD, n (%) | 11 (14%) | 9 (18%) | 2 (8%) | 0.32 |
Atrial fibrillation, n (%) | 19 (25%) | 9 (18%) | 10 (40%) | 0.05 |
Peripheral artery disease, n (%) | 22 (29%) | 14 (27%) | 8 (32%) | 0.79 |
Baseline EuroSCORE II* (%) | 7.6 (3.5–12.9) | 8.9 (6.3–11.5) | 13.1 (9.3–16.9) | 0.07 |
Beta blocker, n (%) | 58 (77%) | 38 (75%) | 20 (83%) | 0.56 |
ACE-Inhibitor/ARB, n (%) | 59 (79%) | 41 (80%) | 18 (75%) | 0.76 |
Statin, n (%) | 45 (60%) | 32 (63%) | 13 (54%) | 0.61 |
Acetylsalicylic acid, n (%) | 31 (42%) | 22 (44%) | 9 (38%) | 0.63 |
Thiazide diuretic, n (%) | 19 (25%) | 14 (27%) | 5 (21%) | 0.78 |
Loop diuretic, n (%) | 48 (65%) | 30 (59%) | 18 (78%) | 0.12 |
Aldosterone antagonist, n (%) | 25 (33%) | 14 (27%) | 11 (46%) | 0.13 |
